Business
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering
Generate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds from the offering are expected to be $400 million, before underwriting discounts and commissions and estimated offering expenses payable by Generate. In addi
About this update from Generate Biomedicines, Inc.
[{"type":"text","content":"SOMERVILLE, Mass., Feb. 26, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds from the offering are expected to be $400 million, before underwriting discounts and commissions and estimated offering expenses payable by Generate. In addition, Generate has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares at the initial public offering price, less underwriting discounts and commissions. All shares are being offered by Generate.","length":792,"tagName":"p"},{"type":"image","alt":"Generate:Biomedicines Logo (PRNewsfoto/Generate:Biomedicines)","displaySize":"","headline":null,"caption":"Generate:Biomedicines Logo (PRNewsfoto/Generate:Biomedicines)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/c02cb5f9e67e94be6a5d3ac22f4a68bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ew6ptY1SS_A9dcmxCAd43Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/c02cb5f9e67e94be6a5d3ac22f4a68bd","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Generate's common stock is expected to begin trading on the Nasdaq Global Select Market on February 27, 2026, under the ticker symbol "GENB." The offering is expected to close on March 2, 2026, subject to customary closing conditions.","length":248,"tagName":"p"},{"type":"text","content":"Goldman Sachs & Co. LLC and Morgan Stanley are acting as joint lead book-running managers for the offering. Piper Sandler, Guggenheim Securities, and Cantor are acting as book-running managers for the offering.","length":214,"tagName":"p"},{"type":"text","content":"A registration statement relating to these securities has been filed and was declared effective by the U.S. Securities and Exchange Commission on February 26, 2026. This offering is being made only by means of a prospectus. A...